e8vk
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 2, 2006
GENOMIC HEALTH, INC.
 
(Exact name of registrant as specified in its charter)
         
Delaware   000-51541   77-0552594
         
(State or Other
Jurisdiction of
Incorporation) 		  (Commission File
Number) 		  (I.R.S. Employer
Identification Number)
     
301 Penobscot Drive
Redwood City, California 		  94063
     
(Address of principal executive offices)   (Zip Code)
(650) 556-3900
(Registrant’s telephone number,
including area code)
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
    o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
    o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
    o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 2.02 Results of Operations and Financial Condition.
Item 9.01 Financial Statements and Exhibits.
SIGNATURE
EXHIBIT INDEX
EXHIBIT 99.1

Table of Contents

Item 2.02 Results of Operations and Financial Condition.
          On May 2, 2006, Genomic Health, Inc. issued a press release announcing financial results for its first fiscal quarter ended March 31, 2006. The full text of the press release is furnished as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
          (d)       Exhibits
99.1       Press release issued by Genomic Health, Inc. dated May 2, 2006.

2

Table of Contents

SIGNATURE
          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
          Dated: May 2, 2006
         
  GENOMIC HEALTH, INC.
 		  
  By:   /s/ G. Bradley Cole    
    (signature)   
    Executive Vice President and
Chief Financial Officer  		  
    (title)   
 

3

Table of Contents

EXHIBIT INDEX
     
Exhibit No.   Description
 
    
99.1
  Press release issued by Genomic Health, Inc. dated May 2, 2006.